Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy

Model scores of the 29,894 trials active now.

Model score 13% for any early termination, 2% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 16% of the time (1,938 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2017-01-20. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Phase: 1 (lowers risk) · Design
• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: metastaticcellscancertumorcell
  Phrases that lowered it: open labelpatients whoclinical trialsafetytrial to
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 12.6% (raises risk) · Sponsor's track record
• Has a data monitoring committee: not given (lowers risk) · Design
• Keywords listed: 20 (raises risk) · Design
• Design: single group (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Drug's FAERS reports with a death: 12.7% (lowers risk) · Drug's FDA history
• Drug's FAERS reports marked serious: 76.0% (lowers risk) · Drug's FDA history
• Minimum age: 18 (raises risk) · Who can join
• Trials the sponsor started in the prior 2 years: 291 (raises risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Blinding: none (raises risk) · Design
• Disease area, respiratory: Yes (raises risk) · Disease area

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment NCT01610336 · started 2012 · scored riskier than 62% of active trials completed
• Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors NCT01324479 · started 2012 · scored riskier than 67% of active trials completed
• Study of ABT-700 in Subjects With Advanced Solid Tumors NCT01472016 · started 2011 · scored riskier than 19% of active trials completed
• A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification NCT02468661 · started 2015 · scored riskier than 72% of active trials terminated
• Study Efficacy and Safety of INC280 in Patients With Advanced Hepatocellular Carcinoma. NCT01737827 · started 2013 · scored riskier than 85% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.